{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:36:38Z","timestamp":1784892998558,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ctro.2023.100708","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:35:23Z","timestamp":1701970523000},"page":"100708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-5686","authenticated-orcid":false,"given":"C.","family":"Yuste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5278-3493","authenticated-orcid":false,"given":"V.","family":"Passerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vaugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Paumier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4602-8204","authenticated-orcid":false,"given":"A.","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CG.","family":"Hemery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Debelleix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chamois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AL.","family":"Septans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctro.2023.100708_b0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2023.100708_b0010","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget April 13"},{"key":"10.1016\/j.ctro.2023.100708_b0015","unstructured":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation."},{"issue":"1","key":"10.1016\/j.ctro.2023.100708_b0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7","article-title":"Metastases in carcinoma. Analysis of 1000 autopsied cases","volume":"3","author":"Abrams","year":"1950","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctro.2023.100708_b0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ctrv.2014.04.001","article-title":"Surgical and ablative therapies for the management of adrenal \u2018oligometastases\u2019 \u2013 A systematic review","volume":"40","author":"Gunjur","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ctro.2023.100708_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jjco\/hyp167","article-title":"Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy","volume":"40","author":"Niibe","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100708_b0035","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100708_b0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer,","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctro.2023.100708_b0045","series-title":"iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics","article-title":"The Lancet. Oncology","author":"Seymour","year":"2017"},{"issue":"5","key":"10.1016\/j.ctro.2023.100708_b0050","first-page":"1323","article-title":"Radiographics : a review publication of the Radiological Society of North America","volume":"33","author":"Tirkes","year":"2013","journal-title":"Inc"},{"issue":"1\u20132","key":"10.1016\/j.ctro.2023.100708_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer\/radioth\u00e9rapie"},{"issue":"1","key":"10.1016\/j.ctro.2023.100708_b0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2023.100708_b0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijrobp.2020.05.062","article-title":"Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors","volume":"110","author":"Stumpf","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100708_b0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ijc.33546","article-title":"Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis","volume":"149","author":"Buergy","year":"2021","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctro.2023.100708_b0075","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.prro.2012.08.006","article-title":"Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease","volume":"3","author":"Corbin","year":"2013","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2023.100708_b0080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10585-021-10124-9","article-title":"Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis","volume":"38","author":"Franzese","year":"2021","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"10.1016\/j.ctro.2023.100708_b0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ctrv.2014.04.001","article-title":"Surgical and ablative therapies for the management of adrenal \u2018oligometastases\u2019 \u2013 A systematic review","volume":"40","author":"Gunjur","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ctro.2023.100708_b0090","doi-asserted-by":"crossref","first-page":"e0195149","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ctro.2023.100708_b0095","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823001337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823001337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:41:13Z","timestamp":1742179273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630823001337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":19,"alternative-id":["S2405630823001337"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100708","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100708"}}